Company Overview of Panacea Pharmaceuticals, Inc.
Panacea Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutic and diagnostic products for treatment of cancer and central nervous system diseases. The company focuses on developing novel proteins and biochemical pathways related to cellular regulation and cell cycle abnormalities in oncology, as well as neurodegenerative diseases such as stroke, Alzheimer's, Parkinson's disease, and chemotherapy-induced cognitive impairment/chemo-brain. Its products include PAN-22, a fully human anti-HAAH monoclonal antibody for the treatment of hepatocellular carcinoma; PAN-622, a toxin conjugate for the treatment of carcinoma of the bile duct; and PAN-811 for the treatment of ischemic s...
209 Perry Parkway
Gaithersburg, MD 20877
Founded in 1999
Key Executives for Panacea Pharmaceuticals, Inc.
Co-Founder, Chairman of the Board, Chief Executive Officer, President and Chief Scientific Officer
Vice President of Medical & Clinical Affairs
Director of Clinical Laboratory Services
Compensation as of Fiscal Year 2017.
Panacea Pharmaceuticals, Inc. Key Developments
Panacea Pharmaceuticals Completes Enrollment in Phase 1 Study of First-In-Class Cancer Vaccine Therapy in Patients with Persistent Prostate Cancer
Feb 1 18
Panacea Pharmaceuticals announced the completion of patient enrollment in an open-label, parallel-designed, multi-center Phase 1 clinical trial of PAN-301-1 for the treatment of persistent prostate cancer to assess safety and immunogenicity. PAN-301-1 is a novel nanoparticle immunotherapy vaccine candidate targeting human aspartyl (asparaginyl) ß-hydroxylase (HAAH) also known as aspartate ß-hydroxylase (ASPH). In the Phase 1 trial, PAN-301-1 is being administered via intradermal injection in patients with biochemically relapsed prostate cancer, using a fixed dose-escalation schema every 21 days to establish the recommended Phase 2 dose. Twelve patients have been enrolled. A minimum of 3 doses of vaccine are administered to each subject. Based on this announced completion of study enrollment, the trial will conclude in the first half of 2018. Highlights of the initial safety and immunogenicity data to date are as follows: The PAN-301-1 therapeutic vaccine has been well tolerated with a highly favorable safety profile across all dose levels in the Phase 1 study; No drug-related adverse events or dose-limiting toxicities have been observed at any of the three vaccine dose levels evaluated; All subjects experienced dose-dependent HAAH-specific immune responses, including antibody levels in immunoassays and B-cell and T-cell responses; A majority of subjects treated beyond 3 months achieved a reduction in Prostate Specific Antigen (PSA) doubling rate (a measure of disease progression) and are receiving continued PAN-301-1 doses at the Investigator's discretion.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries